Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.

  • Luxembourg Center of Neuropathology
January 01, 2020 By:
  • Wefers AK
  • Stichel D
  • Schrimpf D
  • Coras R
  • Pages M
  • Tauziede-Espariat A
  • Varlet P
  • Schwarz D
  • Soylemezoglu F
  • Pohl U
  • Pimentel J
  • Meyer J
  • Hewer E
  • Japp A
  • Joshi A
  • Reuss DE
  • Reinhardt A
  • Sievers P
  • Casalini MB
  • Ebrahimi A
  • Huang K
  • Koelsche C
  • Low HL
  • Rebelo O
  • Marnoto D
  • Becker AJ
  • Staszewski O
  • Mittelbronn M
  • Hasselblatt M
  • Schittenhelm J
  • Cheesman E
  • de Oliveira RS
  • Queiroz RGP
  • Valera ET
  • Hans VH
  • Korshunov A
  • Olar A
  • Ligon KL
  • Pfister SM
  • Jaunmuktane Z
  • Brandner S
  • Tatevossian RG
  • Ellison DW
  • Jacques TS
  • Honavar M
  • Aronica E
  • Thom M
  • Sahm F
  • von Deimling A
  • Jones DTW
  • Blumcke I
  • Capper D.

The "isomorphic subtype of diffuse astrocytoma" was identified histologically in 2004 as a supratentorial, highly differentiated glioma with low cellularity, low proliferation and focal diffuse brain infiltration. Patients typically had seizures since childhood and all were operated on as adults. To define the position of these lesions among brain tumours, we histologically, molecularly and clinically analysed 26 histologically prototypical isomorphic diffuse gliomas. Immunohistochemically, they were GFAP-positive, MAP2-, OLIG2- and CD34-negative, nuclear ATRX-expression was retained and proliferation was low. All 24 cases sequenced were IDH-wildtype. In cluster analyses of DNA methylation data, isomorphic diffuse gliomas formed a group clearly distinct from other glial/glio-neuronal brain tumours and normal hemispheric tissue, most closely related to paediatric MYB/MYBL1-altered diffuse astrocytomas and angiocentric gliomas. Half of the isomorphic diffuse gliomas had copy number alterations of MYBL1 or MYB (13/25, 52%). Gene fusions of MYBL1 or MYB with various gene partners were identified in 11/22 (50%) and were associated with an increased RNA-expression of the respective MYB-family gene. Integrating copy number alterations and available RNA sequencing data, 20/26 (77%) of isomorphic diffuse gliomas demonstrated MYBL1 (54%) or MYB (23%) alterations. Clinically, 89% of patients were seizure-free after surgery and all had a good outcome. In summary, we here define a distinct benign tumour class belonging to the family of MYB/MYBL1-altered gliomas. Isomorphic diffuse glioma occurs both in children and adults, has a concise morphology, frequent MYBL1 and MYB alterations and a specific DNA methylation profile. As an exclusively histological diagnosis may be very challenging and as paediatric MYB/MYBL1-altered diffuse astrocytomas may have the same gene fusions, we consider DNA methylation profiling very helpful for their identification.

2020 Jan. Acta Neuropathol.139(1):193-209. Epub 2019 Sep 28.
Other information